Replies to post #374050 on Amarin Corp Plc (AMRN)

[Dancing in the dark]

Or patent application, or shared rights agreement negotiation between KP and amarin

[ziploc_1]

Dancing...I believe that if the results in Mitigate had been statistically significant, they would have been presented as a late breaking study.

Prepare It 2 in Argentina was trending positive...but was not followed up and has been forgotten.

The Canadian study was a positive pilot study...and has been forgotten


The Canadien Vascepa-Covid study...."Treatment with VASCEPA led to a 25% reduction in the inflammatory biomarker, high sensitivity C-Reactive protein (CRP), which was statistically significant. Treatment with VASCEPA also improved overall symptoms. At the end of the 14-day treatment period, the prevalence of FLU-PRO symptoms was significantly reduced from 100% (at baseline) to 48% - indicating a 52% reduction in symptoms compared to 24% in the untreated patients. The FLU-PRO score is a validated patient-reported outcome measure to evaluate the presence, severity and duration of flu symptoms. Treatment was well tolerated with no major side effects."

I believe that Mitigate will now be followed up and has a good chance of being SS when finally presented.

The recent cancellation at the ACC meeting was a blessing in disguise.